The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 336:952-953 March 27, 1997 Number 13
NextNext

Strategies for the Treatment of Sepsis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
A remarkable number of clinical trials have been performed in the past decade to evaluate drugs for the treatment of sepsis. The mechanism of action of most of these agents is based on one of two unproved assumptions relating to sepsis in humans. The first is that endotoxin (bacterial lipopolysaccharide) contributes to the morbidity and mortality caused by infection with gram-negative bacteria. The second assumption is that a major part of the pathophysiology in patients with sepsis is due to an overproduction of one or many secondarily induced host mediators. The evidence for these widespread beliefs is that when lipopolysaccharide . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.